OIG Flags Kickback Risk in Product-Line Royalties for Physician Consultants
A new HHS OIG advisory opinion warns that royalties tied to broad product-line sales, rather than specific physician innovations, pose a high Anti-Kickback Statute risk even when structured with common compliance safeguards.
The US Department of Health and Human Services' Office of Inspector General (OIG) issued an unfavorable advisory opinion (AO 26-10) on a proposed physician consulting arrangement from an orthopedic device manufacturer. The proposal involved paying physicians a "Product Line Royalty" calculated as a percentage of net sales across an entire product line, not just for specific products the consultant helped develop.
The OIG concluded the arrangement posed a high risk of fraud and abuse under the federal Anti-Kickback Statute (AKS). The agency's primary concern was that the compensation structure could incentivize physicians to leverage their influence—through teaching, training, and proctoring other providers—to drive downstream sales across the product portfolio. This blurs the line between legitimate payment for innovation and a reward for generating business.
Significantly, the OIG remained unconvinced despite several proposed safeguards, including fair market value (FMV) compensation, objective consultant selection criteria, and carve-outs for sales tied to the consultant's own procedures. The opinion signals that FMV alone is not dispositive and that medical device and life sciences companies must carefully link compensation to specific, identifiable development contributions to mitigate AKS risk. Companies should review existing royalty agreements in light of this guidance.